Syngene International Ltd., a leading global Contract Research Organization, announced the expansion of the scope of its R&D collaboration with Baxter Healthcare Corporation, a global healthcare company. As part of the expansion, Syngene will set up additional infrastructure at the dedicated Baxter Global Research Center (BGRC) as well as increase the size of its scientific team working on Baxter projects. The duration of the agreement has also been extended until 2024.
Syngene and Baxter originally established the Baxter Global Research Center, a dedicated R&D center, in 2013. Mr. Jonathan Hunt, Chief Executive Officer, Syngene International Limited, said, “We are very proud of our work with Baxter and the expansion of our collaboration. We advance excellent science at Syngene and our dedicated R&D Center business model allows us to offer integrated scientific solutions to clients.” Syngene presently operates dedicated R&D Centers for Bristol-Myers Squibb, Amgen and Herbalife, in addition to Baxter.